Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments
- Author:
Jaehyun AHN
1
;
Christopher SHIN
;
Yeo Song KIM
;
Jae-Sung PARK
;
Sin-Soo JEUN
;
Stephen AHN
Author Information
- Publication Type:REVIEW ARTICLE
- From:Brain Tumor Research and Treatment 2022;10(3):135-143
- CountryRepublic of Korea
- Language:English
- Abstract: Over the last two decades, numerous studies have investigated the presence of human cytomegalovirus (CMV) within glioblastoma or gliomas; however, the results are severely conflicting. While a few researchers have suggested the potential benefits of cytotoxic T lymphocyte or dendritic cell-based vaccines for recurrent or newly diagnosed glioblastoma patients, several studies did not at all agree with the existence of CMV in glioblastoma cells. In this review, we summarized the conflicting results and issues about the detection of CMV in glioblastoma or glioma patients. We also provided the clinical data of published and unpublished clinical trials using CMV-specific immunotherapy for glioblastomas.
